Autolus Therapeutics (AUTL) Announces $250M Investment from Blackstone (BX) to Advance CAR T Development

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/20/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. ACN
9. AZN
10. SPCX

Go back to Autolus Therapeutics (AUTL) Announces $250M Investment from Blackstone (BX) to Advance CAR T Development

Autolus Therapeutics (AUTL) Announces Publication Describing its Controllable CAR T Cell System

November 10, 2021 7:06 AM EST

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the publication of an article in Nature Scientific Reports describing a controllable CAR T cell system (TetCAR), designed to reversibly dampen the activity of the programmed T cells by the administration of the licensed and widely available antibiotics tetracycline and minocycline.1

Management of toxicities is a critical step in the successful application of programmed cell therapies. TetCAR is one of a number of approaches developed at Autolus that use a pharmacological agent... More

Autolus Therapeutics (AUTL) Deal with Blackstone Overall Positive - Mizuho

November 8, 2021 1:03 PM EST

Mizuho Securities analyst Mara Goldstein reiterated a Buy rating and $18.00 price target on Autolus Therapeutics (NASDAQ: AUTL) after catching up with management following today's Blackstone deal.

Goldstein notes the funding model is minimally dilutive to obe-cel's earning potential and the access to capital... More